Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-LuPSMA STUDY
NCT06288113Phase 2Recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Aug 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Aug 2024; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06288113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06288113.